Biopharma Services
End-to-end drug development support from discovery to commercialization
Service · OtherCompany source
Company profile
About Foundation Medicine
Foundation Medicine is a global, patient-focused precision medicine company that provides high-quality genomic testing solutions for cancer and other diseases. As one of the first companies to recognize the promise of precision medicine, Foundation Medicine has forged the path for comprehensive genomic profiling (CGP) in cancer care. The company offers a portfolio of FDA-approved and laboratory-developed tests that analyze tissue, blood, and bone marrow samples to identify genomic alterations and match patients with targeted therapies and clinical trials. Foundation Medicine's solutions serve healthcare providers throughout the patient journey—from diagnosis to treatment selection to ongoing monitoring. The company has delivered over 1.5 million comprehensive genomic profiling reports and supported more than 950 clinical trials. With historic milestones including 100 approved companion diagnostic indications for next-generation sequencing, Foundation Medicine partners with biopharma companies to accelerate drug discovery and development. The company is expanding its diagnostic capabilities through investments in new technologies and AI-enabled digital platforms to improve outcomes for patients living with cancer and other diseases. Foundation Medicine's core offerings include FoundationOne CDx (tissue-based), FoundationOne Liquid CDx (blood-based), FoundationOne Heme (blood cancers), FoundationOne MRD (molecular residual disease monitoring), and supplemental tests for germline variants and pharmacogenomics.
Company description Foundation Medicine official website
Mission. Transforming lives in cancer and beyond.
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Work at Foundation Medicine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Advanced cancer
- Early stage breast cancer
- Hematologic malignancies
- Lung cancer
- Melanoma
- Sarcomas
- Solid tumors
Who it serves
- Biopharma companies
- Cancer care networks
- Health systems
- Healthcare providers
- Oncologists
- Pathology laboratories
- Patients
- Research institutions
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Recorded integration context: EMR systems (all EMRs mentioned), Pathology Portal.
Geographic context
MarketsGlobal (implied through biopharma partnerships) · United States
Company sourceOfficial website
Company milestones
Platform expansion
FoundationOne CDx approved as first CGP test with group-based companion diagnostic claim for BRAF inhibitors in melanoma (2021-2022). FoundationOne RNA launched for combined DNA + RNA fusion detection. FoundationOne MRD introduced for early stage breast cancer (2025).
Partnerships
Recorded partners
- Biopharma partners for drug development
- Cancer care networks
- Health systems
- Pathology laboratories
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Biopharma Solutions
Comprehensive solutions for drug discovery, development, and commercialization
Service · OtherCompany source
FoundationOne CDx
FDA-approved tissue-based broad companion diagnostic for all solid tumors
Software · OtherCompany source
FoundationOne Germline
Germline testing to identify genetic variants linked to hereditary cancers
Device · OtherCompany source
FoundationOne Heme
Laboratory developed test for hematologic malignancies and sarcomas
Software · OtherCompany source
FoundationOne Liquid CDx
FDA-approved blood-based companion diagnostic for all solid tumors
Software · OtherCompany source
FoundationOne MRD
Minimal residual disease detection for early stage breast cancer
Software · OtherCompany source
FoundationOne PGx
Pharmacogenomic testing for personalized medication management
Software · OtherCompany source
FoundationOne RNA
Combined DNA + RNA fusion detection for comprehensive genomic profiling
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.Clinical genitourinary cancer · Oct 1, 2026
Understanding the Landscape of Clinically Available Molecular Testing.Hematology/oncology clinics of North America · Oct 1, 2026
Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.European journal of cancer (Oxford, England : 1990) · Sep 29, 2026
Association of high tumor mutational burden with brain metastases: Insights from a large-scale database analysis.Neuro-oncology · Sep 26, 2026
CYLD Mutations, PD-L1 and HPV; A Pan-Cancer Landscape Analysis.Research square · Sep 11, 2026
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Sep 3, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Over 1.5 million patient CGP reports delivered
Clinical impact and scale
More than 50% of all approved US CDx indications for NGS testing
Market leadership in companion diagnostics
2,400+ research publications
Scientific evidence base
35+ targeted therapy indications for FoundationOne CDx
Therapeutic matching capability
15+ targeted therapy indications for FoundationOne Liquid CDx
Blood-based diagnostic utility
Summer (Patient)
Stage IV lung cancer diagnosis and treatment planning
ALK mutation identified enabling personalized treatment plan for stage IV lung cancer
other
Research publications using Foundation Medicine data
More than 2,400 research publications, two times more than any other comprehensive genomic profiling (CGP) company
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Jason Adams
Vice President, Head of Biopharma Business Development
Mikael Barmore
Vice President of Clinical Commercial Marketing
Andrea Marengi
Vice President, Deputy General Counsel
Ian Ide
Vice President Talent Acquisition
Winnie Swan
Senior Vice President, Secretary, General Counsel and Chief Compliance Officer
Marcus Thompson, MBA
Vice President of Sales
Dominique Schutz
CFO & Head of Corporate Management
Ronak Shah
Tech Lead
06 · Company updates
Updates from Foundation Medicine
Recent articles published on Foundation Medicine's official website.
The New Era of MRD Testing: Fast, Precise Answers for Patients and Providers
Read on Foundation MedicineA High-Quality Testing Portfolio Grounded in Science – A Research Recap
Read on Foundation MedicineDriving Innovation Together: Helping Biopharmaceutical Partners Deliver Breakthroughs
Read on Foundation MedicineDemonstrating the Clinical Utility of Foundation Medicine’s High-Quality Tests and Proprietary Biomarkers - A Research Recap
Read on Foundation MedicineCelebrating 15 Years of Innovation at Foundation Medicine
Read on Foundation Medicine07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.